1[1]Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ova rian cancer.Br J Cancer, 2000, 82(9):1535
2[2]Rustin GJ, Nelstrop AE, Bentzen SM,et al. Selection of active drugs for ovari an cancer based on CA-125 and standard response rates in phase Ⅱ trials. J Clin Oncol, 2000, 18(8):1733
3[3]Maggino T, Gadducci A.Serum markers as prognostic factors in epithelial ovari an cancer: an overview. Eur J Gynaecol Oncol, 2000,21(1):64
4[4]Hensley ML, Castiel M, Robson ME. Screening for ovarian cancer: what we know, what we need to know. Oncology (Huntingt), 2000,14(11):1601
5[6]Colakovic S, Lukic V, Mitrovic L, et al. Prognostic value of CA125 kinetics a nd half-life in advanced ovarian cancer. Int J Biol Markers, 2000,15(2):147
6[9]Petignat P, Joris F, Obrist R. How CA 125 is used in routine clinical practic e. Eur J Cancer, 2000, 36(15):1933
7[11]Jeyarajah AR, Ind TE, MacDonald N,et al. Increased mortality in postmenopausal women with serum CA125 elevation. Gynecol Oncol,1999, 73(2): 242
8[14]Patsner B, Orr JW, Mann WJ. Use of serum CA125 measurement in post-trea tment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol,19 90,162:427
